Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001222911 | SCV001395034 | pathogenic | Neurofibromatosis, type 1 | 2022-10-13 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 951075). Disruption of this splice site has been observed in individuals with neurofibromatosis type 1 (PMID: 10712197, 20844836). This variant is not present in population databases (gnomAD no frequency). This sequence change affects a donor splice site in intron 8 of the NF1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). For these reasons, this variant has been classified as Pathogenic. |
Gene |
RCV003227010 | SCV003923380 | pathogenic | not provided | 2023-05-04 | criteria provided, single submitter | clinical testing | Canonical splice site variant predicted to result in a null allele in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 34580403, 10712197, 23913538, 20844836, 34439371) |
NHS Central & South Genomic Laboratory Hub | RCV001222911 | SCV005393967 | pathogenic | Neurofibromatosis, type 1 | 2024-11-11 | criteria provided, single submitter | clinical testing | |
Pediatric Genetics Clinic, |
RCV001788426 | SCV001712203 | pathogenic | Café-au-lait macules with pulmonary stenosis | 2021-05-13 | no assertion criteria provided | clinical testing |